We are live on ! Find out more
VCIM

Velan Capital Investment Management Portfolio holdings

AUM $160M
1-Year Est. Return 517.12%
This Fund
S&P 500
This Quarter Est. Return
+104.89%
1 Year Est. Return
+517.12%
3 Year Est. Return
+2,524.89%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$106M
AUM Growth
+$5.23M
Cap. Flow
-$14.9M
Cap. Flow %
-13.95%
Top 10 Hldgs %
68.17%
Holding
61
New
11
Increased
14
Reduced
5
Closed
12

Top Buys

Rank Stock Value
1
LNTH icon
Lantheus
LNTH
+$4.6M
2
ABVX
Abivax
ABVX
+$3.95M
3
JSPR icon
Jasper Therapeutics
JSPR
+$3.74M
4
ZOOZ
ZOOZ Strategy Ltd
ZOOZ
+$3.7M
5
NSPR icon
InspireMD
NSPR
+$3.01M

Top Sells

Rank Stock Value
1
TRML
Tourmaline Bio
TRML
+$10.8M
2
VRNA
Verona Pharma
VRNA
+$8.99M
3
ZVRA icon
Zevra Therapeutics
ZVRA
+$6.3M
4
ARVN icon
Arvinas
ARVN
+$3.68M
5
SCPH
scPharmaceuticals
SCPH
+$3.5M

Sector Composition

Rank Sector Weight
1 Healthcare 95.98%
2 Industrials 4.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CATX icon
51
Perspective Therapeutics
CATX
$372M
– –
-500,000
Closed -$1.72M
FDMT icon
52
4D Molecular Therapeutics
FDMT
$621M
– –
-12,000
Closed -$44.5K
KPRX icon
53
Kiora Pharmaceuticals
KPRX
$11.7M
– –
-122,223
Closed -$352K
LQDA icon
54
Liquidia Corp
LQDA
$7.01B
– –
-239,260
Closed -$2.98M
NKTR icon
55
CALL
Nektar Therapeutics
NKTR
$2.57B
– –
-50,000
Closed -$1.29M
NXTC icon
56
NextCure
NXTC
$37.4M
– –
-3,750
Closed -$20.7K
SCPH
57
DELISTED
scPharmaceuticals
SCPH
– –
-917,668
Closed -$3.5M
VRNA
58
DELISTED
Verona Pharma
VRNA
– –
-95,000
Closed -$8.99M
YARW
59
Yarrow Bioscience, Inc. Common Stock
YARW
$114M
– –
-600
Closed -$49.5K
ZVRA icon
60
Zevra Therapeutics
ZVRA
$679M
– –
-715,000
Closed -$6.3M
UPB
61
Upstream Bio Inc
UPB
$378M
– –
-107,000
Closed -$1.17M
1 2
3

Similar funds

BFAG
Blackston Financial Advisory Group The Villages, Florida $160M AUM 16.38% 1-Year Est. Return
SLG
Sanchez Levi Garrett $159M AUM
SMF
Sterling Manor Financial Saratoga Springs, New York $160M AUM 13.84% 1-Year Est. Return
LCA
Legend Capital Advisors New York $160M AUM
SGCM
Sanchez Gaunt Capital Management Reno, Nevada $160M AUM
RP
RIHO Partners Tucson, Arizona $159M AUM
PCC
Perry Creek Capital New York $160M AUM 3.05% 1-Year Est. Return
RCWM
Royal Capital Wealth Management Carmel, Indiana $161M AUM 18.42% 1-Year Est. Return

Velan Capital Investment Management's Q3 2025 Portfolio in Review

As of Q3 2025, Velan Capital Investment Management held 61 positions worth $106M, up 5.2% from $101M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Velan Capital Investment Management withdrew a net $14.9M in Q3 2025, closing 12 positions and reducing 5 holdings. Its most notable exit was Verona Pharma, an estimated $8.99M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 99% a quarter earlier, followed by Industrials.

Against the trend, Velan Capital Investment Management opened a new position in Lantheus worth $3.77M.

  • Velan Capital Investment Management's largest Q3 2025 buy was Lantheus: 73,545 shares worth $3.77M.
  • Velan Capital Investment Management added most to Jasper Therapeutics in Q3 2025, an estimated $3.74M increase.
  • Velan Capital Investment Management's biggest Q3 2025 reduction was Tourmaline Bio, cutting an estimated $10.8M.
  • Velan Capital Investment Management fully exited Verona Pharma in Q3 2025, selling an estimated $8.99M.
  • Velan Capital Investment Management's ten largest holdings make up 68% of its $106M portfolio in Q3 2025.
  • Velan Capital Investment Management opened 11 new positions and closed 12 in Q3 2025.
  • Velan Capital Investment Management's portfolio value rose 5.2% quarter-over-quarter to $106M.

Based on Velan Capital Investment Management's 13F filing for Q3 2025, filed 14 Nov 2025.